Corvus raises $70.5 million in IPO

Immuno-oncology company Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) raised $70.5 million through the sale of 4.7 million shares at $15 in an IPO underwritten by Credit Suisse, Cowen, Guggenheim and Cantor Fitzgerald. Trading is expected to begin on Wednesday. The offering values Corvus at $306.1 million.

Corvus filed in January to raise up to $115 million. Earlier this month, it said it hoped to sell 4.7 million shares at $15-$17. ...